While more than 4 million people worldwide have an implanted pacemaker or other cardiac rhythm management device, not all of the devices allow their owners to undergo MRIs, an important diagnostic tool to many physicians.
Cancer is still a leading cause of death in America, but cervical cancer death rates have dropped dramatically in the past 40 years, down more than 50 percent, according to the American Cancer Society.
The possibility of tackling lupus, multiple sclerosis and other autoimmune diseases with a new antibody treatment has resulted in a partnership contract between Sanofi and ImmuNext Inc., a firm focused on immunotherapy.
The AbbVie investigational, pan-genotypic, ribavirin-free regimen of glecaprevir (ABT-493)/Pibrentasvir (ABT-530) (G/P) achieved high SVR12 rates after eight weeks of treatment in Japanese patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infections without cirrhosis.
The Abbott EnSite Precision cardiac mapping system and Advisor FL Circular Mapping Catheter, Sensor Enabled to map cardiac arrhythmias during ablation treatments has been used for the first time in the United States.
Volunteers are helping geneticist Michael Snyder and his team advance gadgets such as fitness trackers, smartwatches and wearable health trackers that may one day be able to track diseases including diabetes, Lyme disease and even the common cold before diagnoses are made by doctors.
The kidney health alliance between Vifor Pharma and ChemoCentryx Inc. is expanding to include the development and commercialization of CCX140 which is an orally administered inhibitor of CCR2, a chemokine receptor.
Presenting the year’s most recently approved treatments for cancer, the American Cancer Society recently revealed a brief list of new FDA-endorsed drugs to combat various forms of the disease from its Atlanta hub.